Mekinist drug trial progresses

node leader
29 December 2017

2017 saw the launch in the USA of the Mekinist (Trametinib) clinical trial for EHE patients with progressing EHE. This is the multi-institutional-trial that Dr Rubin had alerted the group to earlier in the year. The trial is led by Dr Schuetze from University of Michigan who is the Principal Investigator. This trial is designed based on Dr Rubin's preclinical research on EHE biology. Dr Rubin is delighted to have 10 patients already enrolled in the trial, and believes that others may be about to join. We are also supporting this trial financially as our EHE group have provided funding for the biopsies that Dr Rubin feels are key so that the real impact of Mekinist on EHE cells can be understood. We wish the trial team continued success with the trial.

As part of the EHE foundations’ patient support role, the group has also established a confidential closed Facebook page for patients taking part in the study so that they may be able to assist each other as they continue through the trial. We wish them all success as they participate in this important trial.

News categories: 

Subscribe to our quarterly newsletter to receive our latest news and information.